Cipla Share Price: Profit **55%** Dhaam Se Gira, Par Stock Phir Bhi **7.9%** Up! Investors Kehte Hain 'Future Hai Boss!'

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Cipla Share Price: Profit **55%** Dhaam Se Gira, Par Stock Phir Bhi **7.9%** Up! Investors Kehte Hain 'Future Hai Boss!'
Overview

Arre yaar, Cipla ke investors ke liye aaj ka din filhaal thoda confusing raha! Company ka profit **55%** gir gaya, lekin iske baad bhi stock seedha **7.9%** upar bhag gaya aur **₹1,432.10** tak pahunch gaya. Sab confuse hain, par reason kya hai?

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Profit Dhadaam, Stock Upar? Ye kaise hua?

Cipla ne Q4 FY26 ke results announce kiye, aur numbers dekh kar thoda dar lag sakta hai. Net profit 55% gir kar sirf ₹554.6 crore reh gaya, jabki revenue bhi 2.8% neeche ₹6,541.2 crore par aa gaya. Operating profit (EBITDA) bhi 35.17% kam ho kar ₹997 crore raha, aur margins 15.2% ho gaye, jo pehle 22.8% the.

Toh phir stock kyu bhaga?

Lagta hai investors ne numbers se zyada future dekha! Market ko umeed hai ki company aage achha perform karegi, especially US market mein. Company ka target hai ki FY27 tak US mein $1 billion ki sales kare. Aur haan, India mein toh unka business mazboot dikha, 15% grow kiya hai.

Par US market mein toh gadbad hai?

Bilkul sahi! North America mein sales 30% kam hui hain constant currency basis par. Iska reason hai gRevlimid ka na hona aur Lanreotide supply mein issues. US generic market mein price ka pressure aur supply chain ki problems dikh rahi hain. FDA ne bhi kuch facilities par warnings di hain, jo supply ko affect kar sakti hain.

Competition aur Aage ka Plan

Dusri companies jaise Dr. Reddy's aur Lupin ke results bhi mix hain. Cipla ne apna Ventolin inhaler ka generic version launch kiya hai, jisse $100 million ki sales ho sakti hai. Par India mein bhi unka market share thoda kam hua hai. FY27 tak $1 billion US sales aur 18.5-20% EBITDA margins ka target achieve karna aasan nahi lag raha, kaafi hurdles hain.

Brokerage Kya Bol Rahe Hain?

Kuch analysts positive hain. JM Financial ne 'Buy' rating aur target ₹1,546 diya hai. Nomura bhi 'Buy' rating ke saath ₹1,510 ka target de raha hai. Lekin Motilal Oswal thoda cautious hai aur 'Neutral' rating ke saath ₹1,380 ka target de raha hai, bol raha hai ki naye products ko market mein set hone mein time lagega.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.